NAMS Earnings & Financial Statements
NewAmsterdam Pharma Company N.V.
$19.71
-$1.87(-8.67%)
--
Overall
--
Value
--
Tech
--
Quality
Market Cap
--
Volume
2.31M
52W Range
$19.58 - $42.21
Target Price
--
NAMS earnings and financial statements: NewAmsterdam Pharma Company N.V.'s income statement, balance sheet and cash flow statement, annual and quarterly.
NAMS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $22.50M | $45.56M | $14.09M | $102.69M |
| Operating income | -$225.68M | -$176.29M | -$182.97M | -$3.56M |
| EBITDA | -$205.00M | -$241.71M | -$176.86M | -$22.34M |
| Net income | -$203.82M | -$241.60M | -$176.94M | -$22.63M |
| EPS (diluted) | $-1.72 | $-2.56 | $-2.15 | $-0.96 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $769.28M | $864.62M | $347.10M | $478.50M |
| Total liabilities | $85.85M | $107.12M | $58.70M | $48.43M |
| Shareholders’ equity | $683.43M | $757.50M | $288.39M | $430.07M |
| Cash and equivalents | $490.00M | $771.74M | $340.45M | $467.73M |
| Long-term debt | $66.0K | $202.0K | - | $60.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$147.78M | -$158.56M | -$141.22M | $10.66M |
| Capital expenditure | -$246.0K | -$672.0K | -$24.0K | -$221.0K |
| Free cash flow | -$148.03M | -$159.24M | -$141.24M | $10.44M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAMS | $19.71 | -8.7% | 2.31M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get NewAmsterdam Pharma Company N.V. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW